Home Biosimilar Antibodies Others Others Apitegromab (Anti-GDF8 / Myostatin)
For research use only. Not for use in humans.

Apitegromab (Anti-GDF8 / Myostatin)

Synonyms: MSTN,GDF8

Apitegromab (Anti-GDF8 / Myostatin) is a fully human monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding to mature myostatin and other closely related growth factors. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. MW: 145.5 KD.

Apitegromab (Anti-GDF8 / Myostatin)

Quality Control

Batch: A248201 Purity: 99% Protein concentration: 13.03mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Apitegromab (Anti-GDF8 / Myostatin) is a fully human monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding to mature myostatin and other closely related growth factors. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. MW: 145.5 KD.

Product Details

CAS No. 2278276-46-1
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07047144 RECRUITING Drug: Apitegromab|Drug: Nusinersen|Drug: Risdiplam Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2; Spinal Muscular Atrophy Type 3; Neuromuscular Manifestations; Anti-myostatin Scholar Rock, Inc. 2025-09-15 PHASE2
NCT07435129 RECRUITING Drug: Apitegromab|Drug: Placebo Facioscapulohumeral Muscular Dystrophy; FSHD Scholar Rock, Inc. 2026-07-30 PHASE2
NCT05626855 ACTIVE_NOT_RECRUITING Drug: Apitegromab Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations; Anti-myostatin Scholar Rock, Inc. 2023-04-17 PHASE3
NCT07473440 COMPLETED Exercise Adaptation; Aerobic Capacity; Athletic Performance; Combat Sports Training Adiyaman University 2025-01-20
NCT06445075 COMPLETED Drug: Apitegromab|Drug: Placebo|Drug: Tirzepatide Overweight and Obesity Scholar Rock, Inc. 2024-05-21 PHASE2
NCT05156320 COMPLETED Drug: Apitegromab|Drug: Placebo Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations; Anti-myostatin Scholar Rock, Inc. 2022-04-14 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-05-01)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.